has some 20-403 higher concentration of copper than skeletal muscle and heart tissues. Despite the severe reduction of copper in neonatal liver of sco2 patients, the concentration is still considerably higher than in heart and skeletal muscle and therefore may be sufficient to permit COX assembly. The copper concentration in skeletal muscle and liver of the sco1 patient was even more severely affected, resulting in concentrations considerably lower than those of tissues from normal individuals of the same age. These observations are consistent with the damaging effect of the sco1 mutation on liver but do not explain the lack of an effect on heart. It should be pointed out that no data were obtained on heart and only one sco1 patient was available for these studies. Obviously, the final answers to the tissue specificity issue will require a more complete analysis of a larger sample of patients.
A recent study in Molecular Cell (Ghisletti et al., 2007) uncovered parallel yet distinct SUMOylation pathways that provide insights into molecular mechanisms of transrepression mediated by activated nuclear receptors LXRa/b and PPARg, thereby clarifying receptor, signal, and gene specificity of transrepression in inflammatory processes.
Transrepression, a key feature of transcriptional crosstalk between nuclear receptors (NRs) and signaling cascades via Toll-like receptors (TLRs), modulates inflammation and immunity in macrophages, lymphocytes, dendritic cells, astrocytes and microglia of the central nervous system, and epithelial cells of the gut. In addition to the well-characterized roles of the glucocorticoid receptor (GR) and peroxisome proliferator-activated receptors (PPARs), the two oxysterol (''liver X'') receptors LXRa and LXRb are now known to play crucial roles in linking cholesterol homeostasis to inflammatory processes and diseases such as atherosclerosis (Castrillo and Tontonoz, 2004) . Work by Tontonoz et al. and others has pointed at the dual functions of both LXR subtypes in macrophages. Via classic ligand activation pathways, LXRs induce genes (e.g., abca1 and apoE) that facilitate cholesterol efflux and can be inhibited by TLR activation (Chawla et al., 2001; Castrillo et al., 2003) . Via classic transrepression pathways, synthetic LXR ligands inhibit lipopolysaccharide (LPS, a TLR4 ligand)-induced expression of NF-kB-regulated genes, which play crucial roles in inflammatory processes (e.g., inducible nitric oxide synthase [inos] and monocyte chemoattractant protein-1 [mcp-1]) . The mechanism involved in regulation of the distinct, overlapping set of inflammatory target genes by transrepressive LXRs and PPARg appeared to be distinct from the repression mediated by GR . Although corepressors were suspected to be involved in these differences, it was the discovery of a small ubiquitin-related modifier (SUMO-1)-dependent pathway that began to resolve this issue. Pascual et al. (2005) showed that SUMOylation of a single lysine residue within the PPARg ligand-binding domain (LBD) prevents LPS-induced and ubiquitination-mediated clearance of N-CoR complexes from signal-responsive promoters. Glass and collaborators have now identified an apparently parallel SUMOylation pathway mediated by LXRs (Ghisletti et al., 2007) and revealed that two distinct pathways are involved in SUMOylation of LXRs and PPARg, respectively ( Figure 1 ). These differences deserve attention as they explain how specificity of transrepression can be achieved in a receptor-, signal-, and promoter-dependent manner.
Covalent conjugation of SUMO (SUMO-1, -2, -3 in mammals) to substrate proteins requires an enzymatic cascade involving one heterodimeric E1 activating enzyme, Ubc9 as an E2 conjugating enzyme that recognizes a specific acceptor site, and various E3 ligases necessary for efficient SUMO transfer and substrate recognition. Knockdown of Ubc9 impaired LXR transrepression and promoter recruitment and abolished the appearance of higher molecular weight-SUMOylated LXRb in an in vivo assay. Surprisingly, in these assays, unlike specific conjugation of SUMO-1 to PPARg, the LXRs were conjugated to the closely related SUMO-2/3. Consistent with this remarkable difference, knockdown of SUMO-1 E3 ligases of the PIAS family, including PIAS1, necessary for SUMO-1 conjugation to PPARg , and of various other established E3s (RanBP2 and PC2), did not affect SUMO-2/3 conjugation to LXRs. Although yeast two-hybrid screenings provided initial clues to the identification of PIAS1 as PPARg E3, a PubMed search guided the authors to identify the missing LXR E3 as HDAC4, a class II family histone deacetylase that contains a C-terminal catalytic deacetylase domain and an N-terminal coiled-coil domain mediating Ubc9 interaction (Zhao et al., 2005) . The identification of HDAC4 as an E3 responsible for SUMO-2/3 conjugation to LXRs is significant. Class II HDACs have been known to assemble with NRs directly or via N-CoR/SMRT corepressor interactions, yet their in vivo role in NR modification and repression has remained puzzling (Fischle et al., 2002) . The LXR ligand activation triggers conversion of apo (ligand-free) to holo (ligand-occupied) and/or sumo (ligand-occupied, SUMO-conjugated) conformational states that either enter (1) the classic activation pathway via RXR-heterodimerization, DNA binding, and coactivator recruitment or (2) the HDAC4/Ubc9-dependent transrepression pathway via specific and reversible conjugation of SUMO-2 (or -3) to one (or two) lysine residues close to LBD helix 12. Entry into one or the other pathway may be LXR ligand selective. In contrast, the PPARg pathway involves SUMO-1 conjugation via PIAS1/Ubc9 to an LBD lysine residue not conserved in LXRs. SUMOylated NRs prevent TLR-signaling-mediated ubiquitin-proteasome-dependent N-CoR clearance from promoters in a receptor-, signal-, and gene-specific manner, consistent with gene expression profiling analysis of transrepression (for details, see Ghisletti et al. [2007] ). Composition/conformations of repressive complexes might be context and signal dependent; assumed direct and probably distinct protein (?) targets for SUMOylated LXRs or PPARg remain enigmatic. Abbreviations: NR, nuclear receptor; LBD, ligand-binding domain; HC, hydroxycholesterol; GW, GW3965 (synthetic agonist); and RXR, 9-cis retinoic acid receptor. possible link between deacetylation and SUMOylation is intriguing, provided that the conserved LBD surfaceexposed acceptor lysine (hLXRb K448, hLXRa K434) adjacent to helix 12 could be subject to cycles of ligand-dependent acetylation (via coactivators) and deacetylation (via HDACs) coupled to SUMOylation (via HDAC4). As the intracellular distribution of class II HDACs can be regulated by phosphorylation and acetylation, HDAC4-mediated SUMOylation of LXRs, and in consequence transrepression by LXRs, might be influenced by a variety of signals.
Glass and collaborators (Ghisletti et al., 2007) provide intriguing details governing the gene-and signalspecific utilization of the LXR versus PPARg transrepression pathway that illustrate how diversity of individual molecular components of two parallel SUMOylation pathways translates into significantly different gene expression outcomes (Figure 1 ). Reevaluation of results from previous gene expression profiling studies identified a number of genes that are repressed only by agonists for one receptor. As both LXRs and PPARg were recruited to all promoters, irrespective of their response status, SUMO-LXRs and SUMO-PPARg seemed to interrupt distinct signaling inputs leading to NCoR clearance. PPARg and LXR ligands exerted additive repressive effects on genes such as inos, which are susceptible to transrepression by both NRs. This additive effect is particularly important for therapeutic scenarios in which combinatorial treatment may be of benefit in treatment of inflammatory diseases. Although the findings of Glass and collaborators are novel and potentially important, it should not be forgotten that the two receptors are functionally firmly linked together because they appear to control each other's expression (Chawla et al., 2001; Seo et al., 2004) . This tight crossregulation might complicate attempts to specifically activate one or the other antiinflammatory pathway.
Future research may focus on identification of the molecular targets of SUMO-2/3-conjugated LXRs and SUMO-1-conjugated PPARg and on their role in preventing N-CoR clearance in response to inflammatory signals. Indeed, recent studies have identified a large number of SUMO-binding proteins carrying conserved motifs, many of which display specificity toward SUMO-1 and SUMO-2/3. Notably, some of these SUMO-binding proteins are implicated in transcriptional repression pathways, for example the lysine demethylase LSD-1 or components of PML complexes (Rosendorff et al., 2006) . Another point that needs to be clarified is whether in vivo pools of SUMO-conjugated versus free LXRs can be limiting for corresponding transrepression (antiinflammatory) versus activation (cholesterol homeostasis) pathways. SUMOylation is a reversible dynamic process highly susceptible to demodification by isopeptidases. Presumably, only a small fraction of SUMOylated proteins will be detectable at steady state in vivo. Future experimental analysis of the ratio and stability of free versus SUMOmodified receptors and of their recruitment to target promoters may require knockdown of SUMO-1 and SUMO-2/3-specific isopeptidases as well as use of SUMO-fusion proteins that mimic key functions of SUMO-conjugates.
Last, but not least, Glass and associates (Ghisletti et al., 2007) argue that, although some oxysterols may both upregulate ABC transporters and downregulate inflammatory responses by transrepressing the NFkB pathway, other oxysterols such as 25-and 27-hydroxycholesterol may affect ABC transporters while lacking transrepression capacity. These differences might relate to varying binding affinities of the oxysterols to LXRs, but this has yet to be tested. It is further possible that these differences might reflect subtype-specific activating characteristics and/or different LXR conformation-inducing properties of the investigated oxysterols. The concept of such ligand-specific conformations, involving the possibility of regulatory receptor surfaces specifically triggering SUMOylation, should stimulate the design of novel pathwayselective synthetic LXR ligands. Considering the problematic role of LXRa in triggering hypertriglyceridemia via SREBP-1c-dependent lipogenesis in the liver, more selective LXRb ligands would be of particular interest. Indeed, LXR pan-agonists are already in clinical trials against atherosclerosis, and efforts are now directed toward developing LXRb-specific agonists.
